Malik Kahook details SpyGlass Pharma (SGP) stock and option holdings

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. director and officer Malik Y. Kahook reports his initial ownership of company securities. He directly holds 873,978 shares of common stock. He also directly holds stock options to purchase 72,389 shares at $2.18, 191,874 shares at $2.87, and 170,475 shares at $7.11 per share.

Each option grant vests over four years under the company’s Amended and Restated 2019 Equity Incentive Plan. For each grant, 25% of the shares vest on the one-year anniversary of its Vesting Commencement Date, with the remaining shares vesting in equal monthly installments thereafter.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Kahook Malik Y.

Role See remarks

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 72,389 shares (Direct); Common Stock — 873,978 shares (Direct)

Footnotes (1)

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 6, 2023. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 20, 2025. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 30, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kahook Malik Y.

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	873,978	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	10/05/2033	Common Stock	72,389	$2.18	D
Stock Option (right to buy)	(2)	04/10/2035	Common Stock	191,874	$2.87	D
Stock Option (right to buy)	(3)	07/23/2035	Common Stock	170,475	$7.11	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 6, 2023.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 20, 2025.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 30, 2025.

Remarks:

President, Chief Medical Officer, Executive Chair Exhibit 24 - Power of Attorney

	/s/ Brian Aukshunas. as Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does SpyGlass Pharma (SGP) Form 3 report for Malik Y. Kahook?

The Form 3 reports Malik Y. Kahook’s initial beneficial ownership in SpyGlass Pharma. He is a director and officer, and the filing lists his directly held common stock and stock options, including quantities, exercise prices, and vesting schedules under the company’s 2019 equity incentive plan.

How many SpyGlass Pharma (SGP) common shares does Malik Y. Kahook own?

Malik Y. Kahook directly owns 873,978 shares of SpyGlass Pharma common stock. This figure is reported as his beneficially owned non-derivative securities on the Form 3 and reflects his direct ownership position as of the event date listed in the filing, February 5, 2026.

What stock options in SpyGlass Pharma (SGP) does Malik Y. Kahook hold?

He holds three direct stock option grants: 72,389 shares at $2.18 expiring October 5, 2033; 191,874 shares at $2.87 expiring April 10, 2035; and 170,475 shares at $7.11 expiring July 23, 2035, all exercisable into SpyGlass Pharma common stock.

How do Malik Y. Kahook’s SpyGlass Pharma (SGP) options vest?

Each option vests over four years under the Amended and Restated 2019 Equity Incentive Plan. Twenty-five percent vests on the one-year anniversary of its Vesting Commencement Date, then one thirty-sixth of the remaining shares vests monthly, subject to continued service as a Service Provider.

What roles does Malik Y. Kahook hold at SpyGlass Pharma (SGP)?

The Form 3 lists him as both a director and an officer of SpyGlass Pharma. The remarks specify his officer roles as President, Chief Medical Officer, and Executive Chair, indicating significant leadership and governance responsibilities within the company’s management and board structure.

What is the event date for Malik Y. Kahook’s SpyGlass Pharma (SGP) Form 3?

The Form 3 uses February 5, 2026, as the Date of Event Requiring Statement. This date anchors when his reported holdings of common stock and derivative securities, including the detailed stock option positions, are being disclosed for regulatory purposes under Section 16(a).